News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Mallinckrodt Pharmaceuticals (MNK) Announces Completion Of MNK-155 Clinical Trials



12/12/2013 10:41:37 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

ST. LOUIS--(BUSINESS WIRE)--Mallinckrodt (NYSE: MNK) today reported positive efficacy results in the Phase 3 clinical trial for MNK-155, an investigational extended-release oral formulation of hydrocodone and acetaminophen studied for the management of moderate to moderately severe acute pain where the use of an opioid analgesic is appropriate. MNK-155 met the primary endpoint in this study.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES